|1.51||-0.0300||-1.95%||Vol 388.06K||1Y Perf -37.40%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||-0.02 -1.32%|
|Target Price||3.50||Analyst Rating||Moderate Buy 1.67|
|Potential %||131.79||Finscreener Ranking||★★★+ 50.95|
|Insiders Trans % 3/6/12 mo.||100/100/67||Value Ranking||★★★+ 53.72|
|Insiders Value % 3/6/12 mo.||100/100/10||Growth Ranking||★+ 43.35|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/46||Income Ranking||— -|
|Price Range Ratio 52W %||40.27||Earnings Rating||Sell|
|Market Cap||149.14M||Earnings Date||11th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.38|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||345.99K|
|Avg. Monthly Volume||842.39K|
|Avg. Quarterly Volume||1.23M|
Adverum Biotechnologies Inc. (NASDAQ: ADVM) stock closed at 1.51 per share at the end of the most recent trading day (a -1.95% change compared to the prior day closing price) with a volume of 388.06K shares and market capitalization of 149.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Adverum Biotechnologies Inc. CEO is Laurent Fischer.
The one-year performance of Adverum Biotechnologies Inc. stock is -37.4%, while year-to-date (YTD) performance is -14.2%. ADVM stock has a five-year performance of -40.78%. Its 52-week range is between 0.79535 and 2.57, which gives ADVM stock a 52-week price range ratio of 40.27%
Adverum Biotechnologies Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of 18.06, a price to cashflow ratio of 242.90, a PEG ratio of 2.32, a ROA of -36.77%, a ROC of -37.33% and a ROE of -45.95%. The company’s profit margin is -%, its EBITDA margin is -1 886.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Adverum Biotechnologies Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Adverum Biotechnologies Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Adverum Biotechnologies Inc. is Moderate Buy (1.67), with a target price of $3.5, which is +131.79% compared to the current price. The earnings rating for Adverum Biotechnologies Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adverum Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Adverum Biotechnologies Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.67, ATR14 : 0.13, CCI20 : -33.61, Chaikin Money Flow : -0.02, MACD : 0.04, Money Flow Index : 37.91, ROC : -0.65, RSI : 38.61, STOCH (14,3) : 60.00, STOCH RSI : 0.94, UO : 56.47, Williams %R : -40.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adverum Biotechnologies Inc. in the last 12-months were: Dawn A. Svoronos (Buy at a value of $25 578), James Scopa (Sold 50 000 shares of value $109 000 ), Julie Clark (Sold 4 766 shares of value $10 342 ), Kishor Peter Soparkar (Buy at a value of $24 994), Laurent Fischer (Buy at a value of $27 800), Peter Soparkar (Buy at a value of $24 994), Richard Beckman (Buy at a value of $8 228), Rupert DÂ¿Souza (Buy at a value of $16 857), Setareh Seyedkazemi (Buy at a value of $16 800)
Sun, 08 May 2022 16:55 GMT Adverum Biotechnologies (ADVM) Receives a Hold from Chardan Capital- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.